摘要:
Objective: To analyze the financial relationships between the healthcare industry and physicians in the clinical neurophysiology ***: There is substantial concern about the potential impact of the physician’s financial relationship with the industry on clinical practice. Transparent reporting of payments to physicians and teaching hospitals from drug and device manufacturers is mandated by the Centers for Medicare and Medicaid Services (CMS) Open Payments Data (OPD) ***/Methods: A retrospective descriptive analysis was performed to characterize the nature, trend, contribution, and distribution of payments using the publicly available CMS OPD database from 2013 to ***: In the Clinical Neurophysiology specialty, 49,482 payments totaled $7.7 million from 2013 to 2018, of which 99.4% of records and 93.4% of values were for general/non-research-related payments. The annual total amount increased from $570,000 in 2013, peaked at $1.65 million in 2015, and dropped to $1.15 million in 2018. Among 3,035 board-certified clinical neurophysiologists, 1,483 (48.9%) received at least one payment from the industry, with the median amount of $142.85 (IQR: $41.83 to $607.50). With respect to the value of payments, the top 10 sponsors contributed to 71.2% of the total amount (ranging from $302,000 to $767,000), and the top 10 anti-epilepsy medications contributed to 36.0% (ranging from $30,000 to $739,000). The top 10 physicians received 56.8% of the total amount of payments (ranging from $129,000 to $1,268,000), of which 85.9% of the values were not related to anti-epilepsy ***: Payments from industry to the clinical neurophysiology, largely driven by non-research related payments, has increased from 2013 to 2015 and declined since then. There was a disparity of payments with respect to the contribution by sponsors as well as distribution to physicians, and the majority of payments were unrelated to anti-epilepsy products.